RIMAG GROUP2522.HKValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 16, 2026, RIMAG GROUP (2522.HK) trades at a negative P/E (-72.92x, due to a recent net loss), P/B of 0.96x, P/S of 2.07x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B sits at the 10th percentile over the trailing 10Y window (vs. 10th percentile over 3Y); P/S sits at the 8th percentile over the trailing 10Y window (vs. 8th percentile over 3Y).
Cross-sectional valuation: its P/B ranks at the 50th percentile within its industry and the 54th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 3.25%, ranking at the 86th percentile over the trailing 20Y window.
Its P/B percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here lean heavily on buybacks rather than cash dividends. RIMAG GROUP operates in the Other Pharmaceuticals and Medical Services sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: HKG: 2522 · SEHK: 2522 · 2522
Want the full picture on whether RIMAG GROUP (2522.HK) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | -72.92 | Negative | Negative | Negative | Negative | Negative | Negative |
| P/B (MRQ) | 0.96 | ||||||
| P/S (TTM) | 2.07 | ||||||
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 3.25% |